- Home
- LDWY vs CYCN Comparison
LDWY vs CYCN Comparison
Compare LDWY & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- CYCN
- Stock Information
- Founded
- LDWY 1990
- CYCN 2018
- Country
- LDWY United States
- CYCN United States
- Employees
- LDWY N/A
- CYCN N/A
- Industry
- LDWY Advertising
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- CYCN Health Care
- Exchange
- LDWY Nasdaq
- CYCN Nasdaq
- Market Cap
- LDWY 9.2M
- CYCN 6.5M
- IPO Year
- LDWY 1991
- CYCN N/A
- Fundamental
- Price
- LDWY $4.99
- CYCN $3.14
- Analyst Decision
- LDWY
- CYCN
- Analyst Count
- LDWY 0
- CYCN 0
- Target Price
- LDWY N/A
- CYCN N/A
- AVG Volume (30 Days)
- LDWY 4.6K
- CYCN 25.9K
- Earning Date
- LDWY 08-18-2025
- CYCN 08-06-2025
- Dividend Yield
- LDWY N/A
- CYCN N/A
- EPS Growth
- LDWY N/A
- CYCN N/A
- EPS
- LDWY N/A
- CYCN N/A
- Revenue
- LDWY $42,183,000.00
- CYCN $2,081,000.00
- Revenue This Year
- LDWY N/A
- CYCN N/A
- Revenue Next Year
- LDWY N/A
- CYCN N/A
- P/E Ratio
- LDWY N/A
- CYCN N/A
- Revenue Growth
- LDWY 425.12
- CYCN N/A
- 52 Week Low
- LDWY $3.02
- CYCN $1.27
- 52 Week High
- LDWY $5.53
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- LDWY 53.76
- CYCN 52.20
- Support Level
- LDWY $4.56
- CYCN $3.05
- Resistance Level
- LDWY $5.14
- CYCN $3.50
- Average True Range (ATR)
- LDWY 0.22
- CYCN 0.27
- MACD
- LDWY -0.02
- CYCN 0.02
- Stochastic Oscillator
- LDWY 59.74
- CYCN 54.43
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.